DURHAM, N.C., Oct. 11, 2018 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host the Company’s annual investor update on October 17, 2018, at 4:30 p.m. ET in New York.
In addition to presentations from management, the event will feature a keynote presentation from Roy F. Chemaly, MD, MPH, Professor, Department of Infectious Diseases, at The University of Texas MD Anderson Cancer Center in Houston.
To access the live webcast, please visit the Investor Relations section of Chimerix’s website at ir.chimerix.com. An archived replay of the webcast will also be available at the same location.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix’s proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix’s website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
ir@chimerix.com
or
Will O’Connor
Stern Investor Relations
will@sternir.com
(212) 362-1200
Media:
Laurie Masonson
W2O Group
lmasonson@w2group.com
(917) 459-6164
